Glenmark Pharmaceuticals Launches GLIPIQ Ⓡ (Semaglutide) in India, Setting New Affordability Benchmark
Mumbai, India, March 21, 2026: Glenmark Pharmaceuticals Ltd (Glenmark) announced the launch of GLIPIQ Ⓡ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM). The launch aims to improve affordability and expand access to advanced diabetes treatment for patients.GLIPIQ Ⓡ is available in both vial and pre-filled pen formulations and has been approved by the Central Drugs Standard Control Organization (CDSCO) following a Phase III clinical study in India. The vial-based formulation, with dose-specific syringes, is intended to offer a more accessible and flexible approach to GLP-1 therapy and a cost-effective treatment pathway.
The expected weekly cost of treatment with GLIPIQ Ⓡ vials ranges from ₹325 to ₹440. The product is available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
Glenmark is also introducing 'Sankalp,' a patient support program (PSP) designed to support therapy initiation, improve comfort with injectable treatment, and enable long-term adherence.
“With GLIPIQ Ⓡ , we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325,” said Mr. Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals Ltd. “The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing.”
Semaglutide is a GLP-1 receptor agonist used in the management of Type 2 Diabetes, particularly in patients with comorbidities such as obesity, atherosclerotic cardiovascular disease (ASCVD), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD).
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led pharmaceutical company with manufacturing facilities across four continents and a commercial footprint in 80+ countries.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.